Dr Reddy's gets Brazil nod for generic semaglutide injection

Dr. Reddy's Laboratories has received marketing authorization from Brazil's National Health Surveillance Agency (ANVISA) for its generic semaglutide injection. This approval is for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. The product will be available in two presentations for once-weekly dosing. Brazil represents a significant market for diabetes treatment, with an estimated semaglutide market of approximately USD 244.6 million. This expansion into Brazil is part of Dr. Reddy's strategy to increase access to this treatment option in markets with substantial patient need.